BRIEF-Arch Biopartners to manufacture drug AB569 with Catalent Inhalation
Aug 10 (Reuters) - Arch Biopartners Inc :
* Engaged Catalent Inhalation, a division of Catalent Pharma Solutions, to begin manufacturing process for drug ab569
* Catalent Inhalation to undertake initial stability and formulation studies, later manufacture a supply of ab569
* Engaged Catalent Inhalation in preparation for first human trials involving patients with antibiotic resistant lung infections Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.